Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

PMID:
27733571
2.

Health Literacy and Outcomes in Multiple Sclerosis.

Henson LJ.

Continuum (Minneap Minn). 2016 Aug;22(3):947-50. doi: 10.1212/CON.0000000000000320.

PMID:
27261691
3.

Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Haselkorn JK, Hughes C, Rae-Grant A, Henson LJ, Bever CT, Lo AC, Brown TR, Kraft GH, Getchius T, Gronseth G, Armstrong MJ, Narayanaswami P.

Neurology. 2015 Nov 24;85(21):1896-903. doi: 10.1212/WNL.0000000000002146. Review.

PMID:
26598432
4.

The pill times 2: what every woman with multiple sclerosis should know.

Henson LJ, Cavalier S, Langer-Gould AM.

Neurology. 2014 Oct 28;83(18):1685. doi: 10.1212/01.wnl.0000456505.44996.b4. No abstract available.

PMID:
25349277
5.

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group.

Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23.

PMID:
24461574
6.

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.

Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, O'Gorman J, Novas M, Dawson KT, Phillips JT.

Curr Med Res Opin. 2014 Feb;30(2):251-62. doi: 10.1185/03007995.2013.849236. Epub 2013 Oct 22. Review.

PMID:
24131282
7.

A personal journey in advocacy.

Henson LJ, May EF.

Neurol Clin Pract. 2013 Feb;3(1):39-43.

PMID:
23634382
8.

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1098-107. Erratum in: N Engl J Med. 2012 Dec 13;367(24):2362.

PMID:
22992073
9.

Vitamin D and multiple sclerosis.

Weinstock-Guttman B, Mehta BK, Ramanathan M, Karmon Y, Henson LJ, Halper J, Riskind P.

Neurologist. 2012 Jul;18(4):179-83. doi: 10.1097/NRL.0b013e31825bbf35. Review.

PMID:
22735240

Supplemental Content

Loading ...
Support Center